I, LARRY KELLY, delegate of the Minister for Health and Ageing for the purposes of section 41CB of the Therapeutic Goods Act 1989 and acting under that section, DETERMINE:
This Order commences on the day after it is registered on the Federal Register of Legislative Instruments.
1 Item No. | 2 Medical Device Standard | 3 Conditions | 4 Essential Principle |
1 | ISO 10993-1: 2003 Biological evaluation of medical devices - Part 1 Evaluation and testing | | Schedule 1, paragraph 7.1(b) |
2 | ISO 10993-3: 2003 Biological evaluation of medical devices - Part 3 Tests for genotoxicity, carcinogenicity and reproductive toxicity | | Schedule 1, paragraph 7.1(b) |
3 | ISO 10993-4: 2002 Biological evaluation of medical devices - Part 4 Selection of tests for interactions with blood AND ISO 10993-4: 2002 Biological evaluation of medical devices - Part 4 Selection of tests for interactions with blood Amendment 1:2006 | | Schedule 1, paragraph 7.1(b) |
4 | ISO 10993-5: 1999 Biological evaluation of medical devices - Part 5 Tests for in vitro cytotoxicity | | Schedule 1, paragraph 7.1(b) |
5 | ISO 10993-6: 2007 Biological evaluation of medical devices - Part 6 Tests for local effects after implantation | | Schedule 1, paragraph 7.1(b) |
6 | ISO 10993-7: 1995 Biological evaluation of medical devices - Part 7 Ethylene oxide sterilization residuals | | Schedule 1, paragraph 7.1(b) |
7 | ISO 10993-9: 1999 Biological evaluation of medical devices - Part 9 Framework for identification and quantification of potential degradation products | | Schedule 1, paragraph 7.1(b) |
8 | ISO 10993-10:2002 Biological evaluation of medical devices - Part 10 Tests for irritation and delayed-type hypersensitivity AND ISO 10933-10:2002 Biological evaluation of medical devices - Part 10 Tests for irritation and delayed- type hypersensitivity Amendment 2006 | | Schedule 1, paragraph 7.1(b) |
9 | ISO 10993-11: 2006 Biological evaluation of medical devices – Part 11 Tests for systemic toxicity | | Schedule 1, paragraph 7.1(b) |
10 | ISO 10993-12: 2007 Biological evaluation of medical devices - Part 12 Sample preparation and reference materials | | Schedule 1, paragraph 7.1(b) |
11 | ISO 10993-13: 1998 Biological evaluation of medical devices - Part 13 Identification and quantification of degradation products from polymeric medical devices | | Schedule 1, paragraph 7.1(b) |
12 | ISO 10993-14: 2001 Biological evaluation of medical devices - Part 14 Identification and quantification of degradation products from ceramics | | Schedule 1, paragraph 7.1(b) |
13 | ISO 10993-15: 2000 Biological evaluation of medical devices - Part 15 Identification and quantification of degradation products from metals and alloys | | Schedule 1, paragraph 7.1(b) |
14 | ISO 10993-16: 1997 Biological evaluation of medical devices - Part 16 Toxicokinetic study design for degradation products and leachables | | Schedule 1, paragraph 7.1(b) |
15 | ISO 10993-17: 2002 Biological evaluation of medical devices – Part 17 Establishment of allowable limits for leachable substances | | Schedule 1, paragraph 7.1(b) |
16 | ISO 10993-18: 2005 Biological evaluation of medical devices – Part 18 Chemical characterization of materials | | Schedule 1, paragraph 7.1(b) |